Genmab — Februar 2018

Solsen

I think they try in short term to keep dara from the market as revlimid is more know and acceptet by now. To buy the combo is a hurdle for both pts and inssurance when CELG dramatically raise pricing.

E_L

I hadn't thought of that... do you know the price difference between Revlimid and Pomalidomide? Someone suggested the Dara/Pom/Dex combo could gain significance / compete
in the US based on price

Solsen

Read that pom are priced $200.000 annually.

Solsen

...and Revlimid $165.000 annually

E_L

ok, so that doesnt makes sense then...

JohnW

I guess a higher price on Revlimid will be an advantage for selling Alcyone then.

Teller

Hello, I am new to this chat, but I have been following it for more than a year now.

Bulder

Yes, or the US-equivalent to VMp: CyBorD

Teller

Maybe the higher price simply reflects a higher demand?

Bulder

The higher the Rev-price goes, the more important is the Dara+CyborD-study, from which we should see data soon.

Teller

Solsen - Hvilken dosis (stand alone eller combo) er denne aarlige behandlingspris baseret paa?

E_L

how much does
CyborD cost?

Bulder

The only drug of the three still patented is bor (Velcade), and it will run out of patent in Europe next year.

Bulder

One unit is DKK 10.051 https://min.medicin.dk/Medicin/Praeparater/3370

Teller

Hvis der anvendes lavere dosis i combo behandling med dara, bliver det vel ikke noedvendigvis mere omkosteligt at behandle. (ud over de +20% om aaret som mere eller mindre er normalen)

Teller

(www.chicagotribune.com)

Bulder

Later this year we

Bulder

... we'll have data from the Cassiopeia study with thalidomide in stead of lenalidomide. So no wonder Celgene raises prices before it's too late.

Solsen

Yes thats what it is. Short CELG

Bulder

The Irish MD, with whom I saw a video the other day, spoke about "financial toxicity", meaning that they wouldn't dream of paying for a Rev-containing combo with dara. And therefore they run their own local Irish study of dara+CyBorD.